Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030766 | 1.00 | ALDH1A1 (0.40) | ALDH1A1DNM1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL13864131 | 1.00 | ALDH1A1 (0.40) | ALDH1A1DNM1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL5159311 | 1.00 | ALDH1A1 (0.40) | ALDH1A1DNM1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL4609242 | 0.96 | ALDH1A1 (0.41) | ALDH1A1DNM1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL2735121 | 0.89 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRL3MBTL1LMNA | |
| SCHEMBL23561835 | 0.88 | DNM1 (0.54) | DNM1TSHRLMNAHTTKMT2A | |
| SCHEMBL4505356 | 0.88 | DNM1 (0.54) | DNM1TSHRLMNAHTTKMT2A | |
| SCHEMBL12588828 | 0.88 | DNM1 (0.54) | DNM1TSHRLMNAHTTKMT2A | |
| SCHEMBL2851674 | 0.88 | DNM1 (0.54) | DNM1TSHRLMNAHTTKMT2A | |
| SCHEMBL5164172 | 0.88 | DNM1 (0.54) | DNM1TSHRLMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037453-B2 | Aromatic polyethers containing a biosourced furan diol | ROQUETTE FRERES (FR) | 2024-07-16 | — | — | US | disclosed |
| US-12037453-B2 | Aromatic polyethers containing a biosourced furan diol | ROQUETTE FRERES (FR) | 2024-07-16 | — | — | US | disclosed |
| US-20230357270-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES | SANOFI (FR) | 2023-11-09 | — | — | US | disclosed |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-9717694-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-8063095-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | PHARMASCIENCE INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-7795298-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2010-09-14 | — | — | US | disclosed |
| US-7589118-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-09-15 | — | — | US | disclosed |
| US-7547724-B2 | IAP BIR domain binding compounds | AEGERA THERPEUTICS, INC. | 2009-06-16 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| EP-0753500-B1 | Process for producing ether compound | KAO CORP (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-5914430-A | REACTING A HYDROXY COMPOUND AND A CARBONYL COMPOUND UNDER HYDROGEN ATMOSPHERE USING CATALYST, REMOVING WATER | KAO CORPORATION (JP) | 1999-06-22 | — | — | US | disclosed |
| EP-0753500-A2 | Process for producing ether compound | KAO CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | ALDH1A1 4074/4885DNM1 1623/4885SMN1; SMN2 1579/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | ALDH1A1 4074/4885DNM1 1623/4885SMN1; SMN2 1579/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | ALDH1A1 3868/4885DNM1 2059/4885SMN1; SMN2 1428/4885 |
| US-20230357270-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES | NFE2L2, KEAP1, NFE2 | ALDH1A1 1088/4885DNM1 4461/4885SMN1; SMN2 2894/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | ALDH1A1 3967/4885DNM1 1753/4885SMN1; SMN2 1535/4885 |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | ALDH1A1 306/4885DNM1 1714/4885SMN1; SMN2 1117/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | ALDH1A1 3433/4885DNM1 2986/4885SMN1; SMN2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.